Posts tagged Probuphine implant
Titan, Opiant collaborate on new approach to opioid use disorder

Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. 

Read More
Braeburn names Mike Derkacz as president, CEO

Closely held Braeburn Pharmaceuticals appointed Michael Derkacz as president and CEO, succeeding Behshad Sheldon, who is stepping down from both posts and as a director, effective immediately, but will continue to serve as a consultant to Braeburn.

Read More
John Hopkins researchers discuss Titan’s Probuphine

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design, Development and Therapy. 

Read More
Titan’s Probuphine featured in Fortune

The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance treatment for opioid addiction.

Read More
Titan’s Probuphine receives patient testimonial

A patient using Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant containing buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction has documented his experience on Janaburson’s Blog.

Read More
Benefits of Titan’s Probuphine featured in DDBN

Drug Deliver Business News has carried an article about Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant, the first marketed product to provide maintenance treatment for opioid addiction continuously for six months following a single administration procedure.

Read More
Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA.

Read More
Titan’s Probuphine, Behshad Sheldon win Stevie awards

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of "Best New Product or Service of the Year."

Read More
Titan’s Probuphine highlighted as a potential game changer

Britain’s Computer Business Review has selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of 10 future technologies that will change the world, along with autonomous vehicles, bionic exoskeletons, deep brain stimulation and Elon Musk's hyperloop, among others.

Read More
Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant and marketing partner, closely-held Braeburn Pharmaceuticals, were featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week.

Probuphine, a subdermal implant of buprenorphine, is the first commercially available six-month maintenance treatment for opioid dependence. The FDA approved Probuphine in May.

Read More
Popular Science picks Titan’s Probuphine for “Best of What’s New” award

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the "12 Most Important Innovations of the Year" in the health category in Popular Science's annual Best of What's New issue.

Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the FDA in May, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

Read More
Titan’s Probuphine gains more media attention

Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.

Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.

Read More
Titan’s Probuphine gains media attention in NYC

New York’s WPIX-TV has produced a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction.

Read More
Titan Pharma receives milestone on Probuphine approval

Titan Pharmaceuticals (NASDAQ:TTNP) has received a $15-million milestone payment from development and commercialization partner, Braeburn Pharmaceuticals, following FDA approval of Probuphine, the first six-month maintenance treatment of opioid dependence.

Under terms of the licensing agreement, closely-held Braeburn will pay Titan tiered royalties on net sales in the U.S. and Canada at rates ranging from the mid-teens to low-twenties. In addition, Titan is eligible for up to $165-million in milestone payments based on achievement of certain annual sales targets.

Read More
Titan’s Probuphine attracts more media attention

The New York Times has published an article about addiction medicines that includes a segment about Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction.

The article quotes Richard Rosenthal, medical director of addiction psychiatry at Mount Sinai Behavioral Health System in New York, who discusses how Probuphine solves three problems associated with opioid maintenance therapy.  The first is the chance of resale or accidental exposure to the pills. “Also, there’s the opportunity for non-adherence — people forget, or don’t take their dose, which leaves them vulnerable again,” he said.  “The other issue mentioned is that medicines have peaks and troughs. “People on various medications may have increased cravings during those troughs.”

Read More